BDRX - Biodexa Pharmaceuticals Plc Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BDRX

BIODEXA PHARMACEUTICALS PLC

NASDAQ

$0.61

▼ DOWN 0.92% (-0.01)

KEY STATISTICS

Market Cap$458.41 K

52w High$59.40

52w Low$0.57

Dividend Yield—

Frequency—

P/E-731.19

Volume103.12K

Shares Out.746.11K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Stephen Anthony Stamp

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 7, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateApr 23, 2027

DayFriday

Rev. Est.—

APR

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-07-29	Reverse	1:10000
2026-04-06	Reverse	1:5
2025-07-31	Reverse	1:10
2024-10-04	Reverse	1:25
2023-07-05	Reverse	1:80
2023-03-27	Reverse	1:4
2022-09-26	Reverse	1:5
2020-03-03	Reverse	1:5
2019-04-08	Reverse	1:10
2018-01-02	Forward	507:500

PRICE

$0.61 ▼ DOWN 0.92% (−$0.01)

OVERLAYS

About Biodexa Pharmaceuticals Plc

https://www.biodexapharma.com ↗

Biodexa Pharmaceuticals Plc, a UK-based clinical-stage biopharma, develops therapies for familial adenomatous polyposis, bladder cancer, Type 1 diabetes, and rare brain cancers, with lead candidates Tolimidone and MTX110 in Phase II and I trials.

INDUSTRY

Biotechnology

A PRODUCT BIODEXA PHARMACEUTICALS PLC IS KNOWN FOR

eRapa™

eRapa, an oral rapamycin tablet for familial adenomatous polyposis (FAP), is in Phase 3 trials, with Orphan Drug Designation from the European Commission, aiming to treat a rare condition that increases colorectal cancer risk.

COMPETITORS

COMPETITOR

AVTX COMPARE

RXRX COMPARE

TPST COMPARE

Biodexa Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

REGULATORY · DECEMBER 2025

Biodexa's Stock Surges Over 100% in Pre-Market Trading Following Enrollment of First European Patients in Pivotal Phase 3 Cancer Trial

In December 2025, Biodexa Pharmaceuticals announced the enrollment of the first European patients in its Phase 3 Serenta trial for eRapa, a potential treatment for Familial Adenomatous Polyposis (FAP), a rare genetic disorder that leads to colorectal cancer. This milestone, supported by a $20 million grant, was met with significant investor optimism, causing the company's stock to surge over 100% in pre-market trading and close with a substantial gain.

MARKET EXPANSION · DECEMBER 2025 · IN PROGRESS

Biodexa Commits to Global Strategy with European Expansion of Pivotal Phase 3 eRapa Trial

Biodexa significantly expanded its strategic focus by activating clinical trial sites and enrolling the first patients in Europe for its pivotal Phase 3 Serenta trial for eRapa. This intentional move transforms the trial into a global program, which is critical for seeking broader regulatory approval and accessing a larger patient population for its lead drug candidate.